These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 15050913)

  • 81. Overexpression of Icat induces G(2) arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, or Axin.
    Sekiya T; Nakamura T; Kazuki Y; Oshimura M; Kohu K; Tago K; Ohwada S; Akiyama T
    Cancer Res; 2002 Jun; 62(11):3322-6. PubMed ID: 12036951
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Therapeutic advances in hepatocellular carcinoma].
    Poupon R; Fartoux L; Rosmorduc O
    Bull Acad Natl Med; 2008 Jan; 192(1):23-31; discussion 31-2. PubMed ID: 18663979
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A nuclear escort for beta-catenin.
    Tolwinski NS; Wieschaus E
    Nat Cell Biol; 2004 Jul; 6(7):579-80. PubMed ID: 15232587
    [No Abstract]   [Full Text] [Related]  

  • 84. Genetic alterations in the Catnb gene but not the H-ras gene in hepatocellular neoplasms and hepatoblastomas of B6C3F(1) mice following exposure to diethanolamine for 2 years.
    Hayashi SM; Ton TV; Hong HH; Irwin RD; Haseman JK; Devereux TR; Sills RC
    Chem Biol Interact; 2003 Dec; 146(3):251-61. PubMed ID: 14642737
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells.
    Cha MY; Kim CM; Park YM; Ryu WS
    Hepatology; 2004 Jun; 39(6):1683-93. PubMed ID: 15185310
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes.
    Cui J; Zhou X; Liu Y; Tang Z; Romeih M
    J Gastroenterol Hepatol; 2003 Mar; 18(3):280-7. PubMed ID: 12603528
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Beta-catenin-accumulated crypt--a novel pre-cancerous condition in rat colorectal neoplasm model].
    Sheng HQ; Lai MD
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):280-2. PubMed ID: 15256131
    [No Abstract]   [Full Text] [Related]  

  • 88. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.
    El-Serag HB; Rudolph KL
    Gastroenterology; 2007 Jun; 132(7):2557-76. PubMed ID: 17570226
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
    CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A global view of hepatocellular carcinoma: trends, risk, prevention and management.
    Yang JD; Hainaut P; Gores GJ; Amadou A; Plymoth A; Roberts LR
    Nat Rev Gastroenterol Hepatol; 2019 Oct; 16(10):589-604. PubMed ID: 31439937
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hepatocellular carcinoma.
    Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS
    Nat Rev Dis Primers; 2021 Jan; 7(1):6. PubMed ID: 33479224
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Hepatocellular carcinoma.
    Forner A; Reig M; Bruix J
    Lancet; 2018 Mar; 391(10127):1301-1314. PubMed ID: 29307467
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
    N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
    Frau M; Feo F; Pascale RM
    J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cancer statistics, 2020.
    Siegel RL; Miller KD; Jemal A
    CA Cancer J Clin; 2020 Jan; 70(1):7-30. PubMed ID: 31912902
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
    Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Primary liver cancer: worldwide incidence and trends.
    Bosch FX; Ribes J; Díaz M; Cléries R
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S5-S16. PubMed ID: 15508102
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma.
    Li K; Yang Y; Ma M; Lu S; Li J
    World J Surg Oncol; 2023 Jul; 21(1):216. PubMed ID: 37481543
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Management of hepatocellular carcinoma: an update.
    Bruix J; Sherman M;
    Hepatology; 2011 Mar; 53(3):1020-2. PubMed ID: 21374666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.